# Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

> **NCT03709771** · — · TERMINATED · sponsor: **Vanderbilt University Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Hypertension
- Melanoma
- Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Ambulatory Blood Pressure Measurement

## Key facts

- **NCT ID:** NCT03709771
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-09
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated due to unmet targeted accrual goals with only 2 subjects accrued out of 80 planned due to COVID-19 and the PI on the grant leaving VUMC in October 2021.
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03709771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03709771, "Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03709771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*